HealthTree

Your Feed

Filter by

See content from

Back to the latest

Thumbnail for Translating Ideas Into Treatment - Dickran Kazandjian, MD | MCRT Miami, Florida May 21, 2022

Playlist: MRT Miami, May 21st, 2022

Translating Ideas Into Treatment - Dickran Kazandjian, MD | MCRT Miami, Florida May 21, 2022

Video details & playlist

Thumbnail for Agne Paner, MD | MCRT Chicago, Illinois April 30, 2022

Playlist: MRT Chicago, April 30th, 2022

Agne Paner, MD | MCRT Chicago, Illinois April 30, 2022

Video details & playlist

How is Frailty Defined in Multiple Myeloma?

How is Frailty Defined in Multiple Myeloma? image

Thumbnail for What are the signs, symptoms, and lab abnormalities of MDS?

Playlist: Myelodysplastic Syndrome (MDS)

What are the signs, symptoms, and lab abnormalities of MDS?

Video details & playlist

Myeloma Round Table: Developing a Treatment Strategy — Chicago, April 30, 2022 (Part 2)

Myeloma Round Table: Developing a Treatment Strategy — Chicago, April 30, 2022 (Part 2) image

Studying Myeloma Progression and Diet: A New Kind of Clinical Trial

Studying Myeloma Progression and Diet: A New Kind of Clinical Trial image

Why I Chose a Myeloma CAR T Clinical Trial at Relapse

Why I Chose a Myeloma CAR T Clinical Trial at Relapse image

Understanding the Difference Between Chemo and Immunotherapies in Myeloma with Dr. Scott Goldsmith

Understanding the Difference Between Chemo and Immunotherapies in Myeloma with Dr. Scott Goldsmith image

Journaling Your Myeloma Story Can Improve Your Health

Journaling Your Myeloma Story Can Improve Your Health image

The Growing Coach Program image

The Growing Coach Program

01:00PM - 02:00PM EDT

Watch Recording

HealthTree Foundation Launches New Journaling Feature for Myelodysplastic Syndromes Patients

HealthTree Foundation Launches New Journaling Feature for Myelodysplastic Syndromes Patients image

Myeloma Round Table: Essential Information for Newly Diagnosed Patients — Chicago, April 30, 2022 (Part 1)

Myeloma Round Table: Essential Information for Newly Diagnosed Patients — Chicago, April 30, 2022 (Part 1) image

Mental Health & AML: Let's Talk About It

Mental Health & AML: Let's Talk About It image

Thumbnail for (Guest Lecture): July 2022 - Capitalizing Life Insurance to Pay for Your Myeloma Care

Playlist: Financial Advice for Myeloma Patients and Their Families

(Guest Lecture): July 2022 - Capitalizing Life Insurance to Pay for Your Myeloma Care

Video details & playlist

Capitalizing Life Insurance to Pay for Your Myeloma Care image

Capitalizing Life Insurance to Pay for Your Myeloma Care

01:00PM - 02:00PM EDT

Watch Recording

Thumbnail for What is the cause of MDS?

Playlist: Myelodysplastic Syndrome (MDS)

What is the cause of MDS?

Video details & playlist

FDA Grants Breakthrough Therapy Designation to Talquetamab for Multiple Myeloma

FDA Grants Breakthrough Therapy Designation to Talquetamab for Multiple Myeloma image

HealthTree Foundation Launches New Journaling Feature for Multiple Myeloma Patients

HealthTree Foundation Launches New Journaling Feature for Multiple Myeloma Patients image

Thumbnail for How do you distinguish between a diagnosis of MDS and AML?

Playlist: Myelodysplastic Syndrome (MDS)

How do you distinguish between a diagnosis of MDS and AML?

Video details & playlist

Myeloma Round Table: Treating Relapsed/Refractory Disease at MD Anderson — Houston, March 26, 2022 (Part 2)

Myeloma Round Table: Treating Relapsed/Refractory Disease at MD Anderson — Houston, March 26, 2022 (Part 2) image

Comparing Black vs. White Myeloma Patient Outcomes

Comparing Black vs. White Myeloma Patient Outcomes image

Mindful Movement and Meditation for AML Patients

Mindful Movement and Meditation for AML Patients image

Balance Part 2: Where to Start and How to Improve

Balance Part 2: Where to Start and How to Improve image

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering

Dr. Eytan Stein will join us to discuss the IDH mutations, treatment options and the recent approval of Tibsovo (ivosidenib) in combination with azacitidine.

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering image

Listen to episode

More from HealthTree